Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Bevacizumab Results Favorable But Not Definitive
Author(s):
Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology.
Related Videos
Related Content
